Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Full Year 2020 and Fourth Quarter (Q4) 2020
Issuance Date: February 3, 2021
GSK reported full-year 2020 results, highlighting strong growth in new and specialty products across HIV, Respiratory, Oncology, and Consumer Healthcare, which offset disruptions to adult vaccinations caused by the COVID-19 pandemic. The company remains on track to separate into two standalone companies (Biopharma and Consumer Healthcare) in 2022.
Key Financial Metrics
| Metric | 2020 Full Year | 2019 Full Year | Growth (AER) | Growth (CER) |
|---|---|---|---|---|
| Turnover | £34.1 billion | £33.8 billion | +1% | +3% |
| Total Operating Profit | £7.8 billion | £7.0 billion | +12% | +15% |
| Adjusted Operating Profit | £8.9 billion | £9.0 billion | -1% | +2% |
| Total EPS | 115.5p | 93.9p | +23% | +26% |
| Adjusted EPS | 115.9p | 123.9p | -6% | -4% |
| Net Cash from Operations | £8.4 billion | £8.0 billion | +5% | - |
| Free Cash Flow | £5.4 billion | £5.1 billion | +7% | - |
| Net Debt | £20.8 billion | £25.2 billion | - | - |
Note: AER = Actual Exchange Rates; CER = Constant Exchange Rates.
Segment Performance (2020)
- Pharmaceuticals: Turnover £17.1 billion (-3% AER, -1% CER). New and specialty products grew +11% AER.
- Vaccines: Turnover £7.0 billion (-2% AER, -1% CER). Shingrix grew +10% AER.
- Consumer Healthcare: Turnover £10.0 billion (+12% AER, +14% CER). Pro-forma CER growth was -2%.
Material Changes vs. Prior Period
- Revenue Drivers: Respiratory sales grew 22% AER driven by Trelegy, Nucala, and Relvar/Breo. HIV sales were flat AER, with growth in Juluca and Dovato offsetting declines in Tivicay and Triumeq. Oncology sales surged 62% AER.
- COVID-19 Impact: Vaccines turnover declined due to reduced demand for Hepatitis, DTPa, Synflorix, and Bexsero vaccines caused by pandemic containment measures. However, Influenza vaccine sales grew 35% AER.
- One-off Items: Total EPS was significantly boosted by a net profit on the disposal of Horlicks and other Consumer Healthcare brands (£2.8 billion gain) and asset disposals. Adjusted EPS declined due to higher non-controlling interest allocations and increased R&D investment.
- Cost Control: Adjusted operating margin was 26.1%, supported by restructuring savings and tight control of ongoing costs, despite increased investment in the pipeline.
Guidance, Outlook, and Risks
2021 Guidance
GSK expects Adjusted EPS for 2021 to decline by a mid to high-single digit percentage at CER. This reflects:
- Continued growth in new and specialty products and Consumer Healthcare.
- Increased investment in the R&D pipeline.
- Deferral of strong growth in Vaccines due to government prioritization of COVID-19 immunization programs impacting adult and adolescent vaccinations (notably Shingrix in the US) in the first half of the year.
Revenue Outlook: Pharmaceuticals expected to grow flat to low-single digits; Consumer Healthcare low to mid-single digits (excluding divested brands); Vaccines flat to low-single digits.
Management Commentary
CEO Emma Walmsley stated that 2020 was a year of significant progress, with the company delivering on guidance despite the pandemic. The company has met all first-year targets for its two-year separation program and is on track to launch two standalone companies in 2022. A new distribution policy for the new GSK will be implemented in 2022, with aggregate distributions expected to be lower than at present to support growth and investment.
Risks and Contingencies
- COVID-19 Pandemic: Ongoing uncertainty regarding the duration and severity of the pandemic, potential impacts on clinical trials, supply continuity, and trading results.
- Legal Matters: Aggregate provision for legal and other disputes was £0.3 billion. The ultimate liability may vary based on litigation outcomes.
- Contingent Consideration: Significant liability of £5.9 billion (post-tax) related to ViiV Healthcare and Novartis Vaccines acquisitions, subject to re-measurement based on sales forecasts and exchange rates.
- Exchange Rates: Strengthening of Sterling against the US Dollar had an adverse impact on reported results.
Investor Verification Checklist
- Adjusted vs. Total EPS: Verify the reconciliation between Total EPS (115.5p) and Adjusted EPS (115.9p), noting the impact of the Horlicks disposal gain and contingent consideration re-measurement charges.
- Vaccines Recovery: Monitor Q1 and Q2 2021 performance of the Vaccines business to assess the severity of the COVID-19 immunization program disruption and the anticipated recovery in H2 2021.
- Separation Progress: Track the execution of the separation preparation program, including the £0.7 billion annual savings target by 2022 and the divestment of non-core assets.
- Pipeline Milestones: Watch for pivotal study data in 2021 for RSV vaccine, COVID-19 assets, and oncology candidates (e.g., dostarlimab, Blenrep).
- Dividend Policy: Confirm the implementation of the new distribution policy in 2022, which is expected to result in lower aggregate distributions compared to current levels.